Table 4.

14-3-3η levels by therapy group at baseline and after 1 year of therapy

Group	Sample size	Pretreatment 14-3-3η	14-3-3η at 1 yr	p Value
Whole cohort	149	0.70 (0.17–5.96)	0.37 (0.11–1.82)	<0.0001
Adalimumab	49	0.62 (0.16–4.66)	0.38 (0.13–1.40)	<0.0001
Methotrexate	23	0.67 (0.17–1.89)	0.33 (0.11–1.44)	0.0101
Tocilizumab	50	0.43 (0.15–8.40)	0.27 (0.10–2.58)	0.0007
Tofacitinib	27	1.30 (0.21–9.46)	1.26 (0.11–3.07)	0.013

Median (interquartile range) 14-3-3η serum titers at baseline and at 1 yr are compared with the whole cohort and each therapy group. Corresponding Wilcoxon matched-pairs signed-rank test values were calculated